Capricor Therapeutics (CAPR) Shares Outstanding (Weighted Average) (2010 - 2026)

Capricor Therapeutics' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $57.4 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 25.85% year-over-year to $57.4 million; the TTM figure through Mar 2026 stood at $57.4 million (up 25.85% YoY), while the FY2025 annual figure was $3.3 million, down 90.5% from the prior year.
• Shares Outstanding (Weighted Average) was $57.4 million for Q1 2026 at Capricor Therapeutics, up from $3.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $57.4 million in Q1 2026 to a low of $105782.0 in Q3 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $27.0 million across 5 years, with a median of $25.8 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) surged 24306.49% in 2023, then slumped 90.5% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $105782.0 in 2022, then soared by 4665.84% to $5.0 million in 2023, then jumped by 598.59% to $35.2 million in 2024, then plunged by 90.5% to $3.3 million in 2025, then soared by 1616.55% to $57.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $57.4 million (Q1 2026), $3.3 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.